UPDATE: J.P. Morgan Upgrades Hologic; Raises PT

Loading...
Loading...
According to a research report published this morning, J.P. Morgan has upgraded Hologic
HOLX
from Neutral to Overweight, and increased PT from $20 to $22. In the report, J.P. Morgan commented, "While we are not constructive on the ultimate returns that are likely to be achieved on the GPRO deal, and we question the top-line outlook for the combined diagnostics segment, we believe that the risk/reward is now too compelling to ignore, in light of the significant potential for cost synergies ($75M+), strong free cash flow generation ($700M+ in 2013E), low probability of further deals in the near term, and now attractive valuation (>15% FCF yield), following a >20% pullback in the stock." Hologic closed Friday at $17.44.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesPrice TargetAnalyst RatingsJ.P. Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...